Your hematocrit rose.
Where did the iron go?
Read beyond the percentage.

Hematocrit describes the fraction of blood volume occupied by red cells. It is not a direct inventory of every red cell circulating in the body. More red-cell volume can raise the fraction, but less plasma can also raise it. Those possibilities are mathematically distinct even when a single laboratory result looks similar.

This does not mean a high value should be dismissed as dehydration. It means the measurement needs context. A repeated pattern, the rest of the blood count, the clinical history and possible contributors are more informative than assuming every elevated reading has the same explanation. Professional guidance explicitly calls for evaluation of elevated hematocrit rather than automatic attribution to testosterone alone.^[5][6][7]

Red-cell count, hemoglobin concentration and hematocrit also have different units and meanings. They are related, but a percentage is not a count and a concentration is not an absolute mass. Keeping those distinctions visible prevents a common error: treating several correlated laboratory values as independent proof of one particular disease.

Polycythemia vera is a distinct hematologic diagnosis. A testosterone-associated rise does not establish it, and its disease-specific treatment goals cannot simply be transferred to everyone whose hematocrit increased. A shared laboratory feature is not the same as a shared cause or a shared evidence base.^[7]

Erythropoietin, usually shortened to EPO, supports red-cell production in bone marrow. Hepcidin regulates access to iron. Hepcidin constrains iron export through ferroportin, the cellular iron-export protein. Lower hepcidin can therefore release part of that restraint, increasing access to iron from absorption and recycling. These are complementary parts of the story: a production signal is of limited use if the material needed for hemoglobin cannot reach developing cells.^[1][9]

In a graded-exposure experiment, 53 younger and 56 older men received weekly testosterone enanthate over 20 weeks while a GnRH agonist suppressed endogenous production. Hepcidin fell early and its later suppression related to subsequent hematocrit changes. Older participants showed a greater response. Importantly, the initial week included a GnRH-associated testosterone flare, so that early change is not a clean estimate of routine steady-state TRT.^[1]

Mouse work adds a molecular hypothesis: testosterone altered hepatic hepcidin transcription and increased incorporation of labeled iron into red cells. That helps explain a route through the system. It does not establish that every intracellular step has been demonstrated in humans, nor does it convert a mechanistic result into a prediction for an individual blood count.^[9]

The useful interpretation is coordinated regulation. Testosterone exposure can change both the request for production and the availability of raw material. The response also depends on the starting state. A hormone concentration alone does not reveal whether iron supply, marrow activity or another factor is limiting the final output.

Iron is needed to build hemoglobin. Ferritin helps assess iron stores, while serum iron and transferrin saturation describe other aspects of circulating availability. These measurements should not be read as interchangeable versions of a single score. More hemoglobin does not necessarily mean more iron remains in reserve.

A lower reserve alongside greater production is not inherently contradictory. It is the difference between material held in storage and material already incorporated into a working structure. That analogy explains the possibility; it does not diagnose iron deficiency from a change in ferritin alone.

The same distinction helps avoid two opposite mistakes. One is assuming a high hemoglobin rules out a problem with iron stores. The other is assuming a falling ferritin automatically explains fatigue or requires a particular intervention. The relevant question is what the complete pattern supports, including the baseline, trajectory and competing explanations.

For readers comparing their experience with online anecdotes, the missing baseline is often decisive. “My ferritin dropped” does not tell us the starting value, other blood loss, concurrent interventions or whether the change persisted. A chronology can generate a hypothesis without establishing its cause. Reporting both the blood-count trend and the iron assessment would make such observations more interpretable, but would still not make them randomized evidence.

The TOM mechanistic analysis followed 166 men who completed six months, from 209 randomized participants. They were at least 65, had mobility limitation and low testosterone, and received testosterone gel or placebo. The parent trial stopped early because of cardiovascular adverse events; this was not a healthy young bodybuilder study.^[2]

EPO rose early, then moved toward baseline despite maintained hematologic changes. The authors proposed a changed EPO/hemoglobin relationship, not simply permanently escalating EPO. Hepcidin and ferritin also changed. A later hormone measurement therefore cannot reconstruct every earlier signal that contributed to the current blood count.^[2]

There is also a demonstrated potential benefit in a different setting. In the TRAVERSE anemia analysis, 815 participants had anemia at baseline. At six months, anemia was corrected in 143 of 349 testosterone-treated men assessed then, versus 103 of 375 receiving placebo: 41.0% versus 27.5%. The intervention was daily 1.62% gel in men with hypogonadism, not an exercise-performance protocol. The six-month denominators are the assessed groups, not the entire baseline anemia cohort.^[8]

Correcting anemia and pushing an already adequate blood count higher are different clinical questions. Evidence for the first should not be presented as proof that the second improves endurance, energy or health. The direction of a laboratory change does not tell us whether that change is beneficial without the starting condition and outcome.

Ory and colleagues examined men receiving testosterone in a large clinical database. Their exposure grouping used hematocrit of at least 52%, followed by propensity matching. This compares people who developed the laboratory finding with those who did not; it does not randomly assign people to different hematocrit targets.^[3]

Baseline hematocrit was higher in the elevated group and could not be matched. The authors could not separate results by testosterone formulation or analyze hematocrit continuously. Comorbidity and limited population diversity also affect generalizability. These limitations prevent treating 52% as a proven biological cliff or the reported event proportion as a personal risk estimate.^[3]

Still, uncertainty is not a reason to ignore the finding. It is a reason to ask the right next question. Does a strategy that changes exposure, treats another contributor or lowers the count improve meaningful outcomes? Those strategies may alter different parts of the causal chain. Similar final laboratory numbers do not establish equivalent benefits or harms.

A threshold used to define a research group is also not automatically an optimal clinical target. Readers should look for the design behind the number: was it a classification chosen by investigators, a monitoring trigger from a guideline, or a target actually compared in a randomized trial? Those categories carry different kinds of evidence.

Removing blood removes red cells and iron. That can lower the circulating red-cell burden while creating a replacement demand. It does not directly erase the androgen exposure or every other factor stimulating production. A subsequent lower hematocrit is therefore only one part of the result.

This donor experiment establishes an important distinction: recovery of the blood count and recovery of iron stores are not identical endpoints. It did not test a repeated-phlebotomy strategy in men continuing testosterone, nor whether iron supplementation in that situation prevents cardiovascular events. Its results cannot supply a universal donation or supplementation schedule.^[4]

Consider the logic of the proposed intervention before asking how frequently to repeat it. Is the aim to address a documented cause, relieve a symptom, lower a measured concentration or prevent an event? An intervention can succeed at one and remain untested at another. That distinction is especially important when repeating the intervention changes a second compartment that is not being followed.

“My hematocrit came down” is a valid observation when documented. “My clotting risk is now normalized” is a stronger claim requiring different evidence. Likewise, a change in ferritin after blood removal is not evidence that the body has become healthier merely because another number moved in the desired direction.

Professional guidance provides clinical action thresholds while acknowledging uncertainty. The Endocrine Society describes withholding testosterone when erythrocytosis develops, evaluation and subsequent adjustment; its monitoring table uses hematocrit greater than 54%. It also identifies therapeutic phlebotomy as effective for lowering hematocrit. Lowering the measurement and proving fewer clinical events remain different statements.^[5]

The AUA also calls for baseline hemoglobin and hematocrit assessment and evaluation when baseline hematocrit is elevated. The current EAU chapter recommends measurements at three, six and twelve months after starting therapy, then annually, with closer surveillance in higher-risk situations. Those schedules describe professional guidance, not proof that one interval suits every patient.^[6][7]

For a reader, the most useful takeaway is the structure of the clinical discussion: confirm the pattern, consider other contributors, assess exposure, and distinguish the intended benefit of any response from its demonstrated outcomes. A number should open that discussion, not replace it.